The Hearty Soul on MSN
Study Suggests Possible Link Between Pfizer COVID-19 Vaccine and Vision-Related Eye Conditions
Public interest has recently turned to the human eye and the Pfizer COVID-19 Vaccine. Two peer-reviewed papers have helped ...
Everyday Health on MSN
Blurry Vision During Exercise
If you have blurred vision while working out or right after an exercise session, it could be a red flag that you’re dealing ...
Investigators reviewed ocular side effects of semaglutide use from a global population-based study across 180 countries. Patients being treated with glucagon-like peptide-1 receptor agonist may ...
ZUG, Switzerland, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on developing innovations for ophthalmic and ...
ZUG, Switzerland, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on innovations addressing neuro-ophthalmic ...
A Prescription Drug User Fee Act target date of February 28, 2026 has been set for the application. The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for ...
Riad Sherif, M.D., Chief Executive Officer of Oculis, commented: “It is a privilege to collaborate with Pitié-Salpêtrière Hospital, a world-renowned center for modern neurology, on the Phase 2 ACUITY ...
ZUG, Switzerland, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on innovations for ophthalmic and ...
Phase 2 ACUITY trial results for Privosegtor (OCS-05) in acute optic neuritis to be presented in EURETINA late-breaking session Expanded data analysis from Phase 3 Stage 1 DIAMOND program for OCS-01 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback